Top

Published in:

Open Access 01-12-2011 | Review

MVP and vaults: a role in the radiation response

Authors: Pedro C Lara, Martin Pruschy, Martina Zimmermann, Luis Alberto Henríquez-Hernández

Published in: Radiation Oncology | Issue 1/2011

Abstract

Vaults are evolutionary highly conserved ribonucleoproteins particles with a hollow barrel-like structure. The main component of vaults represents the 110 kDa major vault protein (MVP), whereas two minor vaults proteins comprise the 193 kDa vault poly(ADP-ribose) polymerase (vPARP) and the 240 kDa telomerase-associated protein-1 (TEP-1). Additionally, at least one small and untranslated RNA is found as a constitutive component. MVP seems to play an important role in the development of multidrug resistance. This particle has also been implicated in the regulation of several cellular processes including transport mechanisms, signal transmission and immune responses. Vaults are considered a prognostic marker for different cancer types. The level of MVP expression predicts the clinical outcome after chemotherapy in different tumour types. Recently, new roles have been assigned to MVP and vaults including the association with the insulin-like growth factor-1, hypoxia-inducible factor-1alpha, and the two major DNA double-strand break repair machineries: non-homologous endjoining and homologous recombination. Furthermore, MVP has been proposed as a useful prognostic factor associated with radiotherapy resistance. Here, we review these novel actions of vaults and discuss a putative role of MVP and vaults in the response to radiotherapy.

Available only for authorised users

Kedersha NL, Heuser JE, Chugani DC, Rome LH: Vaults. III. Vault ribonucleoprotein particles open into flower-like structures with octagonal symmetry. J Cell Biol 1991, 112: 225-235. 10.1083/jcb.112.2.225PubMed

Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995, 1: 578-582. 10.1038/nm0695-578PubMed

Kickhoefer VA, Siva AC, Kedersha NL, Inman EM, Ruland C, Streuli M, Rome LH: The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 1999, 146: 917-928. 10.1083/jcb.146.5.917PubMedCentralPubMed

Kickhoefer VA, Stephen AG, Harrington L, Robinson MO, Rome LH: Vaults and telomerase share a common subunit, TEP1. J Biol Chem 1999, 274: 32712-32717. 10.1074/jbc.274.46.32712PubMed

Kedersha NL, Rome LH: Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA. J Cell Biol 1986, 103: 699-709. 10.1083/jcb.103.3.699PubMed

Tanaka H, Kato K, Yamashita E, Sumizawa T, Zhou Y, Yao M, Iwasaki K, Yoshimura M, Tsukihara T: The structure of rat liver vault at 3.5 angstrom resolution. Science 2009, 323: 384-388. 10.1126/science.1164975PubMed

Xia Y, Ramgopal Y, Li H, Shang L, Srinivas P, Kickhoefer VA, Rome LH, Preiser PR, Boey F, Zhang H, Venkatraman SS: Immobilization of recombinant vault nanoparticles on solid substrates. ACS Nano 2010, 4: 1417-1424. 10.1021/nn901167sPubMed

Yang J, Kickhoefer VA, Ng BC, Gopal A, Bentolila LA, John S, Tolbert SH, Rome LH: Vaults Are Dynamically Unconstrained Cytoplasmic Nanoparticles Capable of Half Vault Exchange. ACS Nano 2010, 4: 7229-7240. 10.1021/nn102051rPubMedCentralPubMed

Kong LB, Siva AC, Kickhoefer VA, Rome LH, Stewart PL: RNA location and modeling of a WD40 repeat domain within the vault. RNA 2000, 6: 890-900. 10.1017/S1355838200000157PubMedCentralPubMed

10.

Kedersha NL, Miquel MC, Bittner D, Rome LH: Vaults. II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes. J Cell Biol 1990, 110: 895-901. 10.1083/jcb.110.4.895PubMed

11.

Mossink MH, van Zon A, Franzel-Luiten E, Schoester M, Kickhoefer VA, Scheffer GL, Scheper RJ, Sonneveld P, Wiemer EA: Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res 2002, 62: 7298-7304.PubMed

12.

Slovak ML, Ho JP, Cole SP, Deeley RG, Greenberger L, de Vries EG, Broxterman HJ, Scheffer GL, Scheper RJ: The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res 1995, 55: 4214-4219.PubMed

13.

Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, et al.: Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995, 87: 1230-1237. 10.1093/jnci/87.16.1230PubMed

14.

Lange C, Walther W, Schwabe H, Stein U: Cloning and initial analysis of the human multidrug resistance-related MVP/LRP gene promoter. Biochem Biophys Res Commun 2000, 278: 125-133. 10.1006/bbrc.2000.3782PubMed

15.

Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004, 75: 163-189.PubMed

16.

Steiner E, Holzmann K, Pirker C, Elbling L, Micksche M, Sutterluty H, Berger W: The major vault protein is responsive to and interferes with interferon-gamma-mediated STAT1 signals. J Cell Sci 2006, 119: 459-469. 10.1242/jcs.02773PubMed

17.

Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P, Scheper RJ: Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. Am J Pathol 1996, 148: 877-887.PubMedCentralPubMed

18.

Kedersha NL, Rome LH: Vaults: large cytoplasmic RNP's that associate with cytoskeletal elements. Mol Biol Rep 1990, 14: 121-122. 10.1007/BF00360441PubMed

19.

Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P, et al.: Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993, 53: 1475-1479.PubMed

20.

Chugani DC, Rome LH, Kedersha NL: Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. J Cell Sci 1993,106(Pt 1):23-29.PubMed

21.

Hamill DR, Suprenant KA: Characterization of the sea urchin major vault protein: a possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport. Dev Biol 1997, 190: 117-128. 10.1006/dbio.1997.8676PubMed

22.

Kolli S, Zito CI, Mossink MH, Wiemer EA, Bennett AM: The major vault protein is a novel substrate for the tyrosine phosphatase SHP-2 and scaffold protein in epidermal growth factor signaling. J Biol Chem 2004, 279: 29374-29385. 10.1074/jbc.M313955200PubMed

23.

Kim E, Lee S, Mian MF, Yun SU, Song M, Yi KS, Ryu SH, Suh PG: Crosstalk between Src and major vault protein in epidermal growth factor-dependent cell signalling. FEBS J 2006, 273: 793-804. 10.1111/j.1742-4658.2006.05112.xPubMed

24.

Yu Z, Fotouhi-Ardakani N, Wu L, Maoui M, Wang S, Banville D, Shen SH: PTEN associates with the vault particles in HeLa cells. J Biol Chem 2002, 277: 40247-40252. 10.1074/jbc.M207608200PubMed

25.

Chung JH, Ginn-Pease ME, Eng C: Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res 2005, 65: 4108-4116. 10.1158/0008-5472.CAN-05-0124PubMed

26.

Yi C, Li S, Chen X, Wiemer EA, Wang J, Wei N, Deng XW: Major vault protein, in concert with constitutively photomorphogenic 1, negatively regulates c-Jun-mediated activator protein 1 transcription in mammalian cells. Cancer Res 2005, 65: 5835-5840. 10.1158/0008-5472.CAN-05-0423PubMed

27.

Iwashita K, Ikeda R, Takeda Y, Sumizawa T, Furukawa T, Yamaguchi T, Akiyama S, Yamada K: Major vault protein forms complexes with hypoxia-inducible factor (HIF)-1alpha and reduces HIF-1alpha level in ACHN human renal adenocarcinoma cells. Cancer Sci 2010, 101: 920-926. 10.1111/j.1349-7006.2009.01481.xPubMed

28.

Kowalski MP, Dubouix-Bourandy A, Bajmoczi M, Golan DE, Zaidi T, Coutinho-Sledge YS, Gygi MP, Gygi SP, Wiemer EA, Pier GB: Host resistance to lung infection mediated by major vault protein in epithelial cells. Science 2007, 317: 130-132. 10.1126/science.1142311PubMedCentralPubMed

29.

Mossink MH, de Groot J, van Zon A, Franzel-Luiten E, Schoester M, Scheffer GL, Sonneveld P, Scheper RJ, Wiemer EA: Unimpaired dendritic cell functions in MVP/LRP knockout mice. Immunology 2003, 110: 58-65. 10.1046/j.1365-2567.2003.01708.xPubMedCentralPubMed

30.

Schroeijers AB, Reurs AW, Scheffer GL, Stam AG, de Jong MC, Rustemeyer T, Wiemer EA, de Gruijl TD, Scheper RJ: Up-regulation of drug resistance-related vaults during dendritic cell development. J Immunol 2002, 168: 1572-1578.PubMed

31.

Berger W, Steiner E, Grusch M, Elbling L, Micksche M: Vaults and the major vault protein: novel roles in signal pathway regulation and immunity. Cell Mol Life Sci 2009, 66: 43-61. 10.1007/s00018-008-8364-zPubMed

32.

Motsch N, Pfuhl T, Mrazek J, Barth S, Grasser FA: Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a. RNA Biol 2007, 4: 131-137. 10.4161/rna.4.3.5206PubMed

33.

Mrazek J, Kreutmayer SB, Grasser FA, Polacek N, Huttenhofer A: Subtractive hybridization identifies novel differentially expressed ncRNA species in EBV-infected human B cells. Nucleic Acids Res 2007, 35: e73. 10.1093/nar/gkm244PubMedCentralPubMed

34.

Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006, 103: 12481-12486. 10.1073/pnas.0605298103PubMedCentralPubMed

35.

Kickhoefer VA, Vasu SK, Rome LH: Vaults are the answer, what is the question? Trends Cell Biol 1996, 6: 174-178. 10.1016/0962-8924(96)10014-3PubMed

36.

Steiner E, Holzmann K, Elbling L, Micksche M, Berger W: Cellular functions of vaults and their involvement in multidrug resistance. Curr Drug Targets 2006, 7: 923-934. 10.2174/138945006778019345PubMed

37.

Suprenant KA: Vault ribonucleoprotein particles: sarcophagi, gondolas, or safety deposit boxes? Biochemistry 2002, 41: 14447-14454. 10.1021/bi026747ePubMed

38.

Hall MD, Handley MD, Gottesman MM: Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci 2009, 30: 546-556. 10.1016/j.tips.2009.07.003PubMedCentralPubMed

39.

Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ: Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 2000, 12: 550-556. 10.1097/00001622-200011000-00007PubMed

40.

Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR, Scheper RJ: Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996, 65: 230-237. 10.1002/(SICI)1097-0215(19960117)65:2<230::AID-IJC17>3.0.CO;2-HPubMed

41.

Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH: Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int J Cancer 1997, 72: 1021-1026. 10.1002/(SICI)1097-0215(19970917)72:6<1021::AID-IJC17>3.0.CO;2-7PubMed

42.

Berger W, Elbling L, Micksche M: Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 2000, 88: 293-300. 10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-SPubMed

43.

Berger W, Spiegl-Kreinecker S, Buchroithner J, Elbling L, Pirker C, Fischer J, Micksche M: Overexpression of the human major vault protein in astrocytic brain tumor cells. Int J Cancer 2001, 94: 377-382. 10.1002/ijc.1486PubMed

44.

Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH: Vaults are up-regulated in multidrug-resistant cancer cell lines. J Biol Chem 1998, 273: 8971-8974. 10.1074/jbc.273.15.8971PubMed

45.

Moran E, Cleary I, Larkin AM, Amhlaoibh RN, Masterson A, Scheper RJ, Izquierdo MA, Center M, O'Sullivan F, Clynes M: Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42. Eur J Cancer 1997, 33: 652-660. 10.1016/S0959-8049(96)00501-1PubMed

46.

Verovski VN, Van den Berge DL, Delvaeye MM, Scheper RJ, De Neve WJ, Storme GA: Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Br J Cancer 1996, 73: 596-602. 10.1038/bjc.1996.103PubMedCentralPubMed

47.

Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T, Akiyama S: Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 1999, 91: 1647-1653. 10.1093/jnci/91.19.1647PubMed

48.

Versantvoort CH, Withoff S, Broxterman HJ, Kuiper CM, Scheper RJ, Mulder NH, de Vries EG: Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer 1995, 61: 375-380. 10.1002/ijc.2910610317PubMed

49.

Wyler B, Shao Y, Schneider E, Cianfriglia M, Scheper RJ, Frey BM, Gieseler F, Schmid L, Twentyman PR, Lehnert M: Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. Br J Haematol 1997, 97: 65-75. 10.1046/j.1365-2141.1997.52649.xPubMed

50.

Ikuta K, Takemura K, Sasaki K, Kihara M, Nishimura M, Ueda N, Naito S, Lee E, Shimizu E, Yamauchi A: Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells. Biol Pharm Bull 2005, 28: 707-712. 10.1248/bpb.28.707PubMed

51.

Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA: Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 2003, 22: 7458-7467. 10.1038/sj.onc.1206947PubMed

52.

Lloret M, Lara PC, Bordon E, Rey A, Falcon O, Apolinario RM, Clavo B, Ruiz A: MVP expression is related to IGF1-R in cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol 2008, 110: 304-307. 10.1016/j.ygyno.2008.04.034PubMed

53.

van den Heuvel-Eibrink MM, Sonneveld P, Pieters R: The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther 2000, 38: 94-110.PubMed

54.

Persson H, Kvist A, Vallon-Christersson J, Medstrand P, Borg A, Rovira C: The non-coding RNA of the multidrug resistance-linked vault particle encodes multiple regulatory small RNAs. Nat Cell Biol 2009, 11: 1268-1271. 10.1038/ncb1972PubMed

55.

Shimamoto Y, Sumizawa T, Haraguchi M, Gotanda T, Jueng HC, Furukawa T, Sakata R, Akiyama S: Direct activation of the human major vault protein gene by DNA-damaging agents. Oncol Rep 2006, 15: 645-652.PubMed

56.

Raval-Fernandes S, Kickhoefer VA, Kitchen C, Rome LH: Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis. Cancer Res 2005, 65: 8846-8852. 10.1158/0008-5472.CAN-05-0770PubMed

57.

Amsel AD, Rathaus M, Kronman N, Cohen HY: Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation. Proc Natl Acad Sci USA 2008, 105: 5117-5122. 10.1073/pnas.0706700105PubMedCentralPubMed

58.

Wang Q, Gao F, May WS, Zhang Y, Flagg T, Deng X: Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway. Mol Cell 2008, 29: 488-498. 10.1016/j.molcel.2007.12.029PubMedCentralPubMed

59.

Lloret M, Lara PC, Bordon E, Fontes F, Rey A, Pinar B, Falcon O: Major vault protein may affect nonhomologous end-joining repair and apoptosis through Ku70/80 and bax downregulation in cervical carcinoma tumors. Int J Radiat Oncol Biol Phys 2009, 73: 976-979. 10.1016/j.ijrobp.2008.11.013PubMed

60.

Ryu SJ, An HJ, Oh YS, Choi HR, Ha MK, Park SC: On the role of major vault protein in the resistance of senescent human diploid fibroblasts to apoptosis. Cell Death Differ 2008, 15: 1673-1680. 10.1038/cdd.2008.96PubMed

61.

Ryu SJ, Park SC: Targeting major vault protein in senescence-associated apoptosis resistance. Expert Opin Ther Targets 2009, 13: 479-484. 10.1517/14728220902832705PubMed

62.

Minaguchi T, Waite KA, Eng C: Nuclear localization of PTEN is regulated by Ca(2+) through a tyrosil phosphorylation-independent conformational modification in major vault protein. Cancer Res 2006, 66: 11677-11682. 10.1158/0008-5472.CAN-06-2240PubMed

63.

Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ, et al.: PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010, 2: 53ra75. 10.1126/scitranslmed.3001538PubMed

64.

Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A: Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1: 315-322. 10.1002/emmm.200900041PubMedCentralPubMed

65.

Mitchell JB, Russo A, Cook JA, Glatstein E: Tumor cell drug and radiation resistance: does an interrelationship exist? Cancer Treat Res 1989, 48: 189-203. 10.1007/978-1-4613-1601-5_12PubMed

66.

Bottke D, Koychev D, Busse A, Heufelder K, Wiegel T, Thiel E, Hinkelbein W, Keilholz U: Fractionated irradiation can induce functionally relevant multidrug resistance gene and protein expression in human tumor cell lines. Radiat Res 2008, 170: 41-48. 10.1667/RR0986.1PubMed

67.

Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager U, Geissler K, Lechner K, Pirker R: Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 1998, 91: 1508-1513.PubMed

68.

Filipits M, Stranzl T, Pohl G, Heinzl H, Jager U, Geissler K, Fonatsch C, Haas OA, Lechner K, Pirker R: Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia 2000, 14: 68-76. 10.1038/sj.leu.2401634PubMed

69.

Pirker R, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jager U, Geissler K, Lechner K, Filipits M: The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia. Adv Exp Med Biol 1999, 457: 133-139. 10.1007/978-1-4615-4811-9_15PubMed

70.

Xu D, Arestrom I, Virtala R, Pisa P, Peterson C, Gruber A: High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone. Br J Haematol 1999, 106: 627-633. 10.1046/j.1365-2141.1999.01611.xPubMed

71.

Oh EJ, Kahng J, Kim Y, Kim M, Lim J, Kang CS, Min WS, Cho B, Lee A, Lee KY, et al.: Expression of functional markers in acute lymphoblastic leukemia. Leuk Res 2003, 27: 903-908. 10.1016/S0145-2126(03)00026-2PubMed

72.

Valera ET, Scrideli CA, Queiroz RG, Mori BM, Tone LG: Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia. Sao Paulo Med J 2004, 122: 166-171. 10.1590/S1516-31802004000400007PubMed

73.

Volm M, Stammler G, Zintl F, Koomagi R, Sauerbrey A: Expression of lung resistance-related protein (LRP) in initial and relapsed childhood acute lymphoblastic leukemia. Anticancer Drugs 1997, 8: 662-665. 10.1097/00001813-199708000-00003PubMed

74.

Ohno N, Tani A, Uozumi K, Hanada S, Furukawa T, Akiba S, Sumizawa T, Utsunomiya A, Arima T, Akiyama S: Expression of functional lung resistance--related protein predicts poor outcome in adult T-cell leukemia. Blood 2001, 98: 1160-1165. 10.1182/blood.V98.4.1160PubMed

75.

Sakaki Y, Terashi K, Yamaguchi A, Kawamata N, Tokito Y, Mori H, Umehara M, Yoshiyama T, Ohtsubo H, Arimura K, et al.: Human T-cell lymphotropic virus type I Tax activates lung resistance-related protein expression in leukemic clones established from an adult T-cell leukemia patient. Exp Hematol 2002, 30: 340-345. 10.1016/S0301-472X(02)00775-0PubMed

76.

Filipits M, Drach J, Pohl G, Schuster J, Stranzl T, Ackermann J, Konigsberg R, Kaufmann H, Gisslinger H, Huber H, et al.: Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin Cancer Res 1999, 5: 2426-2430.PubMed

77.

Rimsza LM, Campbell K, Dalton WS, Salmon S, Willcox G, Grogan TM: The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. Leuk Lymphoma 1999, 34: 315-324.PubMed

78.

Schwarzenbach H: Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002, 19: 87-104. 10.1385/MO:19:2:87PubMed

79.

Brinkhuis M, Izquierdo MA, Baak JP, van Diest PJ, Kenemans P, Scheffer GL, Scheper RJ: Expression of multidrug resistance-associated markers, their relation to quantitative pathologic tumour characteristics and prognosis in advanced ovarian cancer. Anal Cell Pathol 2002, 24: 17-23.PubMed

80.

Wang W, Ke S, Chen G, Gao Q, Wu S, Wang S, Zhou J, Yang X, Lu Y, Ma D: Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. Oncol Rep 2004, 12: 1365-1370.PubMed

81.

Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, et al.: Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 1999, 5: 2798-2805.PubMed

82.

Mayr D, Pannekamp U, Baretton GB, Gropp M, Meier W, Flens MJ, Scheper R, Diebold J: Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol Res Pract 2000, 196: 469-475. 10.1016/S0344-0338(00)80048-5PubMed

83.

Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K: RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res 2003, 9: 827-836.PubMed

84.

Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A, Martin M: Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 2000, 20: 4373-4377.PubMed

85.

Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, Cantonati H, Attems J, Gsur A, Micksche M: Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 2005, 131: 355-363. 10.1007/s00432-004-0653-9PubMed

86.

Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST, Kao A: Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 2003, 181: 267-273. 10.1007/s00408-003-1029-7PubMed

87.

Komdeur R, Klunder J, van der Graaf WT, van den Berg E, de Bont ES, Hoekstra HJ, Molenaar WM: Multidrug resistance proteins in rhabdomyosarcomas: comparison between children and adults. Cancer 2003, 97: 1999-2005. 10.1002/cncr.11259PubMed

88.

Komdeur R, Plaat BE, van der Graaf WT, Hoekstra HJ, Hollema H, van den Berg E, Zwart N, Scheper RJ, Molenaar WM: Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer 2003, 39: 909-916. 10.1016/S0959-8049(03)00029-7PubMed

89.

Diestra JE, Condom E, Del Muro XG, Scheffer GL, Perez J, Zurita AJ, Munoz-Segui J, Vigues F, Scheper RJ, Capella G, et al.: Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J Urol 2003, 170: 1383-1387. 10.1097/01.ju.0000074710.96154.c9PubMed

90.

Schadendorf D, Makki A, Stahr C, van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM: Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 1995, 147: 1545-1552.PubMedCentralPubMed

91.

Mandoky L, Geczi L, Doleschall Z, Bodrogi I, Csuka O, Kasler M, Bak M: Expression and prognostic value of the lung resistance-related protein (LRP) in germ cell testicular tumors. Anticancer Res 2004, 24: 1097-1104.PubMed

92.

Tews DS, Nissen A, Kulgen C, Gaumann AK: Drug resistance-associated factors in primary and secondary glioblastomas and their precursor tumors. J Neurooncol 2000, 50: 227-237. 10.1023/A:1006491405010PubMed

93.

Silva P, West CM, Slevin N, Valentine H, Ryder WD, Hampson L, Bibi R, Sloan P, Thakker N, Homer J, Hampson I: Tumor expression of major vault protein is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007, 69: 133-140. 10.1016/j.ijrobp.2007.02.025PubMed

94.

Lloret M, Lara PC, Bordon E, Pinar B, Rey A, Falcon O, Molano F, Hernandez MA: IGF-1R expression in localized cervical carcinoma patients treated by radiochemotherapy. Gynecol Oncol 2007, 106: 8-11. 10.1016/j.ygyno.2007.04.004PubMed

95.

Ramani P, Dewchand H: Expression of mdr1/P-glycoprotein and p110 in neuroblastoma. J Pathol 1995, 175: 13-22. 10.1002/path.1711750104PubMed

96.

Dingemans AM, van Ark-Otte J, van der Valk P, Apolinario RM, Scheper RJ, Postmus PE, Giaccone G: Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol 1996, 7: 625-630.PubMed

97.

Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G: Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 1997, 71: 787-795. 10.1002/(SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.0.CO;2-5PubMed

98.

Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R: Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 1997, 79: 2336-2344. 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-JPubMed

99.

Pohl G, Filipits M, Suchomel RW, Stranzl T, Depisch D, Pirker R: Expression of the lung resistance protein (LRP) in primary breast cancer. Anticancer Res 1999, 19: 5051-5055.PubMed

100.

Volm M, Rittgen W: Cellular predictive factors for the drug response of lung cancer. Anticancer Res 2000, 20: 3449-3458.PubMed

101.

Goff BA, Paley PJ, Greer BE, Gown AM: Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol Oncol 2001, 81: 18-24. 10.1006/gyno.2000.6105PubMed

102.

Pohl G, Suchomel RW, Stranzl T, Depisch D, Stiglbauer W, Filipits M, Pirker R: Expression of the lung resistance protein in primary colorectal carcinomas. Anticancer Res 2001, 21: 201-204.PubMed

103.

Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M: Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 2003, 94: 394-399. 10.1111/j.1349-7006.2003.tb01453.xPubMed

Title: MVP and vaults: a role in the radiation response
Authors: Pedro C Lara
Martin Pruschy
Martina Zimmermann
Luis Alberto Henríquez-Hernández
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-6-148

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MVP and vaults: a role in the radiation response

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes

The in vivo study on the radiobiologic effect of prolonged delivery time to tumor control in C57BL mice implanted with Lewis lung cancer

Preliminary comp arison of helical tomotherapy and mixed beams of unmodulated electrons and intensity modulated radiation therapy for treating superficial cancers of the parotid gland and nasal cavity

Current measures of metabolic heterogeneity within cervical cancer do not predict disease outcome

Adjuvant or radical fractionated stereotactic radiotherapy for patients with pituitary functional and nonfunctional macroadenoma

Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study